Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients - Biognosys

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

This webinar reveals how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities. Jean-Marie Michot, a medical oncologist at Gustave Roussy Institute and Vito Dozio, Scientific Project Manager at Biognosys, share a study that illustrates the promise of proteomics in understanding responses to new therapies such as anti-IL-6-based treatment and the impact of comorbidities on clinical outcomes.

GenomeWebinar April 27, 2021
Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Back to Resources overview

Helpdesk

Access our knowledge base with relevant resources and guiding information.

Contact

    Close banner

    Spectronaut® 16

    The Deepest Proteome
    Coverage Available

    New: Spectronaut® 16

    The Deepest Proteome Coverage Available

    learn more